Clinical Trials
7 trialsNCT04037254 2026-05-20
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT04295577 2026-05-13
MONITOR-UK
Royal Marsden NHS Foundation Trust
Completed
NCT04313504 2026-05-07
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
University of Cincinnati
Phase 2 Completed
NCT04475939 2026-05-01
ZEAL-1L
GlaxoSmithKline
Phase 3 Completed
NCT05021562 2026-04-13
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Takeda
Completed
NCT03601923 2026-03-25
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed